- News & Events
- Contact Us
Amgen Names Phyllis Piano Vice President, Corporate Communications and Philanthropy
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Sept. 2, 2005--Amgen (Nasdaq:AMGN) today announced the appointment of Phyllis Piano to the position of vice president, Corporate Communications and Philanthropy. Piano will be responsible for the company's strategic communications platform, including internal and external communications, public relations, communications issues management, master brand management, web communications and Amgen's philanthropy efforts.
Piano joins Amgen after serving as vice president, Corporate Affairs and Communications at Raytheon Company, a $20 billion aerospace and defense company, and a member of Raytheon's leadership team. Prior to joining Raytheon, she served as vice president, Public Affairs for Cooper Industries, Inc., a manufacturer of electrical products, tools and hardware, and automotive products. Piano also spent 17 years at General Electric where she progressed through positions of increasing responsibility in communications, including her role as head of communications at GE Medical Systems.
Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a broad and deep pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.
EDITOR'S NOTE: An electronic version of this news release may be accessed via our Web site at www.amgen.com. Journalists and media representatives may sign up to receive all news releases electronically at time of announcement by filling out a short form in the Media section of the Web site.
CONTACT: Amgen, Thousand Oaks Mary Klem, 805-447-4587 (media) Arvind Sood, 805-447-1060 (investors) SOURCE: Amgen